Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.

Press Release 03.2019: Oncoinvent is pleased to announce that it has received a manufacturing authorization (GMP certificate) for production of Radspherin® clinical trial material from the Norwegian Medicine Agency.

Press Release 02.2019: Oncoinvent has signed an agreement with the Institute of Energy Technology (IFE) for the distribution of Radspherin (investigational medicinal products) to sites and institutions as part of the company’s clinical trial program.

Press Release 02.2019. Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several years also within the life science industry. He holds an MBA from the Norwegian Business School, BI and is a Certified European Financial Analyst (CEFA) from the Norwegian School of Economics.

Press Release 07.2018. Oncoinvent announces that Radspherin® research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).

Oncoinvent Research Scientist Elisa Napoli

Press Release 06.2018: Oncoinvent is pleased to announce that research scientist Elisa Napoli presented Radspherin® research findings earlier this week during the Monday morning Novel Radiochemistry session at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Philadelphia, USA.

Press Release 05.2018: Oncoinvent is pleased to announce today that it has fulfilled the necessary requirements stipulated by the Research Council of Norway and is now eligible to receive 12 MNOK in BIA project funding to help develop its lead product Radspherin®.

Press Release 04.2018: Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected.

Press Release 03.2018: Oncoinvent publishes data explaining Radspherin® `s mechanism of action

Press Release 02.2018: Oncoinvent is pleased to announce today that Oncoinvent has been selected to receive BIA project funding from the Research Council of Norway to help develop its lead product Radspherin®.

Add Your Heading Text Here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Add Your Heading Text Here

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close